The effects of antidepressants in Parkinson's disease: a meta-analysis. Review uri icon

Overview

abstract

  • This study explored the therapeutic effect of antidepressants in Parkinson's disease (PD) using a meta-analysis. Altogether, 24 placebo-controlled trials qualified for inclusion and revealed that tricyclic antidepressants (TCAs) had a greater antidepressant effect relative to selective serotonin reuptake inhibitors (SSRIs), Qb(1) = 8.87, p < .01, and the mono-amine-oxidase inhibitor, selegiline, Qb(1) = 7.90, p < .01. Whereas TCAs produced a significant side effect profile (odds ratio = 3.07), adverse events were negligible with SSRIs (odds ratio = 1.83) and selegeline (odds ratio = 1.63). Antidepressants can be beneficial for patients with PD. However, the choice of antidepressants needs to take depressive symptomatologies into account while monitoring side effects.

publication date

  • May 1, 2008

Research

keywords

  • Antidepressive Agents
  • Parkinson Disease

Identity

Scopus Document Identifier

  • 43049121419

Digital Object Identifier (DOI)

  • 10.1080/00207450701239418

PubMed ID

  • 18446583

Additional Document Info

volume

  • 118

issue

  • 5